Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-07-23

AUTHORS

Shuichi Ito, Yoshihiko Hidaka, Norimitsu Inoue, Shinya Kaname, Hideki Kato, Masanori Matsumoto, Yoshitaka Miyakawa, Masashi Mizuno, Hirokazu Okada, Akihiko Shimono, Takahisa Matsuda, Shoichi Maruyama, Yoshihiro Fujimura, Masaomi Nangaku, Shoji Kagami

ABSTRACT

BackgroundIn 2013, eculizumab was approved for treatment of the atypical hemolytic–uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of “aHUS” to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA.MethodsPediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event–free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed.ResultsIn 27 pediatric patients with aHUS, median age at diagnosis was 4 years. Complement genes’ variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0 days. TMA event–free status, complete TMA response, platelet normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported.ConclusionsThis interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting. More... »

PAGES

112-121

Journal

TITLE

Clinical and Experimental Nephrology

ISSUE

1

VOLUME

23

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10157-018-1610-2

DOI

http://dx.doi.org/10.1007/s10157-018-1610-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105776110

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30039480


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atypical Hemolytic Uremic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement C5", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement Inactivating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement System Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Variation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glomerular Filtration Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant, Newborn", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Function Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Product Surveillance, Postmarketing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Shuichi", 
        "id": "sg:person.012302533312.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412568.c", 
          "name": [
            "Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hidaka", 
        "givenName": "Yoshihiko", 
        "id": "sg:person.01366756522.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366756522.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.489169.b", 
          "name": [
            "Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inoue", 
        "givenName": "Norimitsu", 
        "id": "sg:person.010564733752.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010564733752.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411205.3", 
          "name": [
            "Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaname", 
        "givenName": "Shinya", 
        "id": "sg:person.0632351573.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632351573.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kato", 
        "givenName": "Hideki", 
        "id": "sg:person.01275753007.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275753007.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Masanori", 
        "id": "sg:person.013301731152.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013301731152.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.430047.4", 
          "name": [
            "Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyakawa", 
        "givenName": "Yoshitaka", 
        "id": "sg:person.01317475506.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317475506.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.27476.30", 
          "name": [
            "Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuno", 
        "givenName": "Masashi", 
        "id": "sg:person.01211430102.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211430102.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Saitama Medical University, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410802.f", 
          "name": [
            "Saitama Medical University, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okada", 
        "givenName": "Hirokazu", 
        "id": "sg:person.0700630035.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700630035.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimono", 
        "givenName": "Akihiko", 
        "id": "sg:person.014764522454.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014764522454.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuda", 
        "givenName": "Takahisa", 
        "id": "sg:person.014167142054.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014167142054.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.27476.30", 
          "name": [
            "Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maruyama", 
        "givenName": "Shoichi", 
        "id": "sg:person.01106355134.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106355134.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410775.0", 
          "name": [
            "Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujimura", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.0724065021.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724065021.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nangaku", 
        "givenName": "Masaomi", 
        "id": "sg:person.01300062465.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300062465.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.267335.6", 
          "name": [
            "Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kagami", 
        "givenName": "Shoji", 
        "id": "sg:person.01227336036.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227336036.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10157-013-0856-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040454736", 
          "https://doi.org/10.1007/s10157-013-0856-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12882-016-0420-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046165114", 
          "https://doi.org/10.1186/s12882-016-0420-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10157-011-0452-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018993111", 
          "https://doi.org/10.1007/s10157-011-0452-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10157-016-1276-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023786470", 
          "https://doi.org/10.1007/s10157-016-1276-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10157-013-0911-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015777021", 
          "https://doi.org/10.1007/s10157-013-0911-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12882-015-0195-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044460496", 
          "https://doi.org/10.1186/s12882-015-0195-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10157-015-1142-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010236054", 
          "https://doi.org/10.1007/s10157-015-1142-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-07-23", 
    "datePublishedReg": "2018-07-23", 
    "description": "BackgroundIn 2013, eculizumab was approved for treatment of the atypical hemolytic\u2013uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of \u201caHUS\u201d to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA.MethodsPediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event\u2013free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed.ResultsIn 27 pediatric patients with aHUS, median age at diagnosis was 4\u00a0years. Complement genes\u2019 variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0\u00a0days. TMA event\u2013free status, complete TMA response, platelet normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported.ConclusionsThis interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10157-018-1610-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5898832", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6835634", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1117096", 
        "issn": [
          "1342-1751", 
          "1437-7799"
        ], 
        "name": "Clinical and Experimental Nephrology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "atypical hemolytic uremic syndrome", 
      "post-marketing surveillance", 
      "event-free status", 
      "complete TMA response", 
      "secondary thrombotic microangiopathy", 
      "thrombotic microangiopathy", 
      "hemolytic uremic syndrome", 
      "pediatric patients", 
      "interim analysis", 
      "adverse reactions", 
      "Shiga toxin-producing Escherichia", 
      "observational real-world study", 
      "complement-mediated HUS", 
      "platelet count normalization", 
      "Japanese pediatric patients", 
      "glomerular filtration rate", 
      "thrombotic thrombocytopenic purpura", 
      "complement gene variants", 
      "effectiveness of eculizumab", 
      "real-world study", 
      "MethodsPediatric patients", 
      "platelet normalization", 
      "TMA patients", 
      "median age", 
      "thrombocytopenic purpura", 
      "median time", 
      "meningococcal infection", 
      "clinical endpoints", 
      "filtration rate", 
      "eculizumab initiation", 
      "clinical guide", 
      "eculizumab", 
      "BackgroundIn 2013", 
      "patients", 
      "real-world setting", 
      "aHUS patients", 
      "TMA response", 
      "count normalization", 
      "gene variants", 
      "syndrome", 
      "diagnosis", 
      "surveillance", 
      "status", 
      "safety", 
      "microangiopathy", 
      "purpura", 
      "EGFR", 
      "infection", 
      "endpoint", 
      "response", 
      "death", 
      "normalization", 
      "age", 
      "treatment", 
      "HUS", 
      "cause", 
      "variants", 
      "approval", 
      "days", 
      "improvement", 
      "initiation", 
      "years", 
      "setting", 
      "effectiveness", 
      "analysis", 
      "study", 
      "rate", 
      "Escherichia", 
      "Japan", 
      "use", 
      "reaction", 
      "guide", 
      "time", 
      "terms"
    ], 
    "name": "Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic\u2013uremic syndrome in Japan: interim analysis of post-marketing surveillance", 
    "pagination": "112-121", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105776110"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10157-018-1610-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30039480"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10157-018-1610-2", 
      "https://app.dimensions.ai/details/publication/pub.1105776110"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_780.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10157-018-1610-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1610-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1610-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1610-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1610-2'


 

This table displays all metadata directly associated to this object as RDF triples.

383 TRIPLES      22 PREDICATES      128 URIs      113 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10157-018-1610-2 schema:about N00ae007b9ab8437cb24bc1f184a9b354
2 N1cdf2d5a6e4c4245a8a6b42dc94f4d12
3 N46c36c3a65f94a12a46c26f851abfb72
4 N46ec12e5f3534adeaa28ec17b69606ed
5 N52625165e5024a8296bcf1ac7ff5617b
6 N53bf94eba7664415bebd4a89d941c400
7 N55474c690e4445ee9500bcdf7cf0d723
8 N590650a5dcb14646af6207221e346a87
9 N5a2370826cf740b1add4266d5ebb8429
10 N73f4dd42e485473c867b4ee8c0a60f3c
11 N762971709fd74b83aab332c7496cb6ec
12 N7713f3a98dcd4346bbb468dbc5549f32
13 N793a66411f8d4691b0ec16fdd7c96d42
14 N80dcb4afca544fa98ccaac422eb48200
15 N81bba5c459e54a5786985db49b9c475c
16 N90e11eb7fc1a4c30bc8461207ed5ef07
17 N985c2e412651442e936576a78695be11
18 N9e079ad60d7f462faa57f39735024973
19 Na16a164efea244b6a3143ec0cd1ad3fe
20 Nc4203cf0c0574a4396c163bedbf46ea4
21 Nfd8d7da67ebf49dba774cd0b21055245
22 anzsrc-for:11
23 anzsrc-for:1117
24 schema:author N2ccda5a58eb9448ba41d950576884315
25 schema:citation sg:pub.10.1007/s10157-011-0452-y
26 sg:pub.10.1007/s10157-013-0856-y
27 sg:pub.10.1007/s10157-013-0911-8
28 sg:pub.10.1007/s10157-015-1142-y
29 sg:pub.10.1007/s10157-016-1276-6
30 sg:pub.10.1186/s12882-015-0195-1
31 sg:pub.10.1186/s12882-016-0420-6
32 schema:datePublished 2018-07-23
33 schema:datePublishedReg 2018-07-23
34 schema:description BackgroundIn 2013, eculizumab was approved for treatment of the atypical hemolytic–uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of “aHUS” to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA.MethodsPediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event–free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed.ResultsIn 27 pediatric patients with aHUS, median age at diagnosis was 4 years. Complement genes’ variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0 days. TMA event–free status, complete TMA response, platelet normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported.ConclusionsThis interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N36bf3a4c45214e19bde0c7241e916ddc
39 Ne7364004452143a88642dabe4e8de8ff
40 sg:journal.1117096
41 schema:keywords BackgroundIn 2013
42 EGFR
43 Escherichia
44 HUS
45 Japan
46 Japanese pediatric patients
47 MethodsPediatric patients
48 Shiga toxin-producing Escherichia
49 TMA patients
50 TMA response
51 aHUS patients
52 adverse reactions
53 age
54 analysis
55 approval
56 atypical hemolytic uremic syndrome
57 cause
58 clinical endpoints
59 clinical guide
60 complement gene variants
61 complement-mediated HUS
62 complete TMA response
63 count normalization
64 days
65 death
66 diagnosis
67 eculizumab
68 eculizumab initiation
69 effectiveness
70 effectiveness of eculizumab
71 endpoint
72 event-free status
73 filtration rate
74 gene variants
75 glomerular filtration rate
76 guide
77 hemolytic uremic syndrome
78 improvement
79 infection
80 initiation
81 interim analysis
82 median age
83 median time
84 meningococcal infection
85 microangiopathy
86 normalization
87 observational real-world study
88 patients
89 pediatric patients
90 platelet count normalization
91 platelet normalization
92 post-marketing surveillance
93 purpura
94 rate
95 reaction
96 real-world setting
97 real-world study
98 response
99 safety
100 secondary thrombotic microangiopathy
101 setting
102 status
103 study
104 surveillance
105 syndrome
106 terms
107 thrombocytopenic purpura
108 thrombotic microangiopathy
109 thrombotic thrombocytopenic purpura
110 time
111 treatment
112 use
113 variants
114 years
115 schema:name Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
116 schema:pagination 112-121
117 schema:productId N052eb3f0ba904405917ec1e369fcdc6c
118 N4e3de5855e14438bae31d50cf28a7409
119 N75dcf28f77bf4ec59d6a0a4cfe01af49
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105776110
121 https://doi.org/10.1007/s10157-018-1610-2
122 schema:sdDatePublished 2022-05-10T10:22
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher N14a73d18eb794f4891fab3eeb9f83230
125 schema:url https://doi.org/10.1007/s10157-018-1610-2
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N00ae007b9ab8437cb24bc1f184a9b354 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N052eb3f0ba904405917ec1e369fcdc6c schema:name dimensions_id
133 schema:value pub.1105776110
134 rdf:type schema:PropertyValue
135 N085f71b7f6e2428f8d3ec85a7a8c4efa rdf:first sg:person.014167142054.61
136 rdf:rest N2853a051da5e45c7af6c8ada9ebb0ba1
137 N14a73d18eb794f4891fab3eeb9f83230 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N1b81c68cfe8e46439e6cd8b2d3140f97 rdf:first sg:person.01300062465.65
140 rdf:rest Nb6aebbd3acb7441ba34f088a3e127130
141 N1cdf2d5a6e4c4245a8a6b42dc94f4d12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Product Surveillance, Postmarketing
143 rdf:type schema:DefinedTerm
144 N2853a051da5e45c7af6c8ada9ebb0ba1 rdf:first sg:person.01106355134.42
145 rdf:rest Need40f294327409a81a8b9490c016061
146 N2ccda5a58eb9448ba41d950576884315 rdf:first sg:person.012302533312.63
147 rdf:rest Nd1994bcafd1e4894a68e83514131377c
148 N36bf3a4c45214e19bde0c7241e916ddc schema:issueNumber 1
149 rdf:type schema:PublicationIssue
150 N45c2a2e62e884f019ed02d7a6e8a29a8 rdf:first sg:person.0632351573.32
151 rdf:rest N7c40756a6f18433599df9c1b86f76713
152 N46c36c3a65f94a12a46c26f851abfb72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Complement Inactivating Agents
154 rdf:type schema:DefinedTerm
155 N46ec12e5f3534adeaa28ec17b69606ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Japan
157 rdf:type schema:DefinedTerm
158 N4a7b75f7f05d4553899193debb14dc0e rdf:first sg:person.01211430102.94
159 rdf:rest N77eb004e8c054cbd8c0a9e5483443377
160 N4e3de5855e14438bae31d50cf28a7409 schema:name doi
161 schema:value 10.1007/s10157-018-1610-2
162 rdf:type schema:PropertyValue
163 N52625165e5024a8296bcf1ac7ff5617b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Child
165 rdf:type schema:DefinedTerm
166 N53bf94eba7664415bebd4a89d941c400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Glomerular Filtration Rate
168 rdf:type schema:DefinedTerm
169 N55474c690e4445ee9500bcdf7cf0d723 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Patient Safety
171 rdf:type schema:DefinedTerm
172 N590650a5dcb14646af6207221e346a87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Complement C5
174 rdf:type schema:DefinedTerm
175 N5a2370826cf740b1add4266d5ebb8429 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Genetic Variation
177 rdf:type schema:DefinedTerm
178 N70afaaf605f04e1db35fb355978f05d8 rdf:first sg:person.01317475506.36
179 rdf:rest N4a7b75f7f05d4553899193debb14dc0e
180 N73f4dd42e485473c867b4ee8c0a60f3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Male
182 rdf:type schema:DefinedTerm
183 N75dcf28f77bf4ec59d6a0a4cfe01af49 schema:name pubmed_id
184 schema:value 30039480
185 rdf:type schema:PropertyValue
186 N762971709fd74b83aab332c7496cb6ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Adolescent
188 rdf:type schema:DefinedTerm
189 N7713f3a98dcd4346bbb468dbc5549f32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Kidney Function Tests
191 rdf:type schema:DefinedTerm
192 N77eb004e8c054cbd8c0a9e5483443377 rdf:first sg:person.0700630035.01
193 rdf:rest N97dcd3e1eb114425acff2e246a0f5eaa
194 N793a66411f8d4691b0ec16fdd7c96d42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Complement System Proteins
196 rdf:type schema:DefinedTerm
197 N7c40756a6f18433599df9c1b86f76713 rdf:first sg:person.01275753007.55
198 rdf:rest Na10c3d197ee14a56b6968c2dc7906a75
199 N80dcb4afca544fa98ccaac422eb48200 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Humans
201 rdf:type schema:DefinedTerm
202 N81bba5c459e54a5786985db49b9c475c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Child, Preschool
204 rdf:type schema:DefinedTerm
205 N90e11eb7fc1a4c30bc8461207ed5ef07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Antibodies, Monoclonal, Humanized
207 rdf:type schema:DefinedTerm
208 N96e39a826de5438a93fdb63bde8a33a5 rdf:first sg:person.010564733752.03
209 rdf:rest N45c2a2e62e884f019ed02d7a6e8a29a8
210 N97dcd3e1eb114425acff2e246a0f5eaa rdf:first sg:person.014764522454.27
211 rdf:rest N085f71b7f6e2428f8d3ec85a7a8c4efa
212 N985c2e412651442e936576a78695be11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Atypical Hemolytic Uremic Syndrome
214 rdf:type schema:DefinedTerm
215 N9e079ad60d7f462faa57f39735024973 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Infant
217 rdf:type schema:DefinedTerm
218 Na10c3d197ee14a56b6968c2dc7906a75 rdf:first sg:person.013301731152.54
219 rdf:rest N70afaaf605f04e1db35fb355978f05d8
220 Na16a164efea244b6a3143ec0cd1ad3fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Platelet Count
222 rdf:type schema:DefinedTerm
223 Nb6aebbd3acb7441ba34f088a3e127130 rdf:first sg:person.01227336036.26
224 rdf:rest rdf:nil
225 Nc4203cf0c0574a4396c163bedbf46ea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Treatment Outcome
227 rdf:type schema:DefinedTerm
228 Nd1994bcafd1e4894a68e83514131377c rdf:first sg:person.01366756522.36
229 rdf:rest N96e39a826de5438a93fdb63bde8a33a5
230 Ne7364004452143a88642dabe4e8de8ff schema:volumeNumber 23
231 rdf:type schema:PublicationVolume
232 Need40f294327409a81a8b9490c016061 rdf:first sg:person.0724065021.42
233 rdf:rest N1b81c68cfe8e46439e6cd8b2d3140f97
234 Nfd8d7da67ebf49dba774cd0b21055245 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Infant, Newborn
236 rdf:type schema:DefinedTerm
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
241 schema:name Public Health and Health Services
242 rdf:type schema:DefinedTerm
243 sg:grant.5898832 http://pending.schema.org/fundedItem sg:pub.10.1007/s10157-018-1610-2
244 rdf:type schema:MonetaryGrant
245 sg:grant.6835634 http://pending.schema.org/fundedItem sg:pub.10.1007/s10157-018-1610-2
246 rdf:type schema:MonetaryGrant
247 sg:journal.1117096 schema:issn 1342-1751
248 1437-7799
249 schema:name Clinical and Experimental Nephrology
250 schema:publisher Springer Nature
251 rdf:type schema:Periodical
252 sg:person.010564733752.03 schema:affiliation grid-institutes:grid.489169.b
253 schema:familyName Inoue
254 schema:givenName Norimitsu
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010564733752.03
256 rdf:type schema:Person
257 sg:person.01106355134.42 schema:affiliation grid-institutes:grid.27476.30
258 schema:familyName Maruyama
259 schema:givenName Shoichi
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106355134.42
261 rdf:type schema:Person
262 sg:person.01211430102.94 schema:affiliation grid-institutes:grid.27476.30
263 schema:familyName Mizuno
264 schema:givenName Masashi
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211430102.94
266 rdf:type schema:Person
267 sg:person.01227336036.26 schema:affiliation grid-institutes:grid.267335.6
268 schema:familyName Kagami
269 schema:givenName Shoji
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227336036.26
271 rdf:type schema:Person
272 sg:person.012302533312.63 schema:affiliation grid-institutes:grid.268441.d
273 schema:familyName Ito
274 schema:givenName Shuichi
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63
276 rdf:type schema:Person
277 sg:person.01275753007.55 schema:affiliation grid-institutes:grid.26999.3d
278 schema:familyName Kato
279 schema:givenName Hideki
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275753007.55
281 rdf:type schema:Person
282 sg:person.01300062465.65 schema:affiliation grid-institutes:grid.26999.3d
283 schema:familyName Nangaku
284 schema:givenName Masaomi
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300062465.65
286 rdf:type schema:Person
287 sg:person.01317475506.36 schema:affiliation grid-institutes:grid.430047.4
288 schema:familyName Miyakawa
289 schema:givenName Yoshitaka
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317475506.36
291 rdf:type schema:Person
292 sg:person.013301731152.54 schema:affiliation grid-institutes:grid.410814.8
293 schema:familyName Matsumoto
294 schema:givenName Masanori
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013301731152.54
296 rdf:type schema:Person
297 sg:person.01366756522.36 schema:affiliation grid-institutes:grid.412568.c
298 schema:familyName Hidaka
299 schema:givenName Yoshihiko
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366756522.36
301 rdf:type schema:Person
302 sg:person.014167142054.61 schema:affiliation grid-institutes:None
303 schema:familyName Matsuda
304 schema:givenName Takahisa
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014167142054.61
306 rdf:type schema:Person
307 sg:person.014764522454.27 schema:affiliation grid-institutes:None
308 schema:familyName Shimono
309 schema:givenName Akihiko
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014764522454.27
311 rdf:type schema:Person
312 sg:person.0632351573.32 schema:affiliation grid-institutes:grid.411205.3
313 schema:familyName Kaname
314 schema:givenName Shinya
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632351573.32
316 rdf:type schema:Person
317 sg:person.0700630035.01 schema:affiliation grid-institutes:grid.410802.f
318 schema:familyName Okada
319 schema:givenName Hirokazu
320 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700630035.01
321 rdf:type schema:Person
322 sg:person.0724065021.42 schema:affiliation grid-institutes:grid.410775.0
323 schema:familyName Fujimura
324 schema:givenName Yoshihiro
325 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724065021.42
326 rdf:type schema:Person
327 sg:pub.10.1007/s10157-011-0452-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1018993111
328 https://doi.org/10.1007/s10157-011-0452-y
329 rdf:type schema:CreativeWork
330 sg:pub.10.1007/s10157-013-0856-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1040454736
331 https://doi.org/10.1007/s10157-013-0856-y
332 rdf:type schema:CreativeWork
333 sg:pub.10.1007/s10157-013-0911-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015777021
334 https://doi.org/10.1007/s10157-013-0911-8
335 rdf:type schema:CreativeWork
336 sg:pub.10.1007/s10157-015-1142-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010236054
337 https://doi.org/10.1007/s10157-015-1142-y
338 rdf:type schema:CreativeWork
339 sg:pub.10.1007/s10157-016-1276-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023786470
340 https://doi.org/10.1007/s10157-016-1276-6
341 rdf:type schema:CreativeWork
342 sg:pub.10.1186/s12882-015-0195-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044460496
343 https://doi.org/10.1186/s12882-015-0195-1
344 rdf:type schema:CreativeWork
345 sg:pub.10.1186/s12882-016-0420-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046165114
346 https://doi.org/10.1186/s12882-016-0420-6
347 rdf:type schema:CreativeWork
348 grid-institutes:None schema:alternateName Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan
349 schema:name Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan
350 rdf:type schema:Organization
351 grid-institutes:grid.267335.6 schema:alternateName Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan
352 schema:name Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan
353 rdf:type schema:Organization
354 grid-institutes:grid.268441.d schema:alternateName Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan
355 schema:name Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan
356 rdf:type schema:Organization
357 grid-institutes:grid.26999.3d schema:alternateName Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
358 schema:name Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
359 rdf:type schema:Organization
360 grid-institutes:grid.27476.30 schema:alternateName Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan
361 schema:name Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan
362 rdf:type schema:Organization
363 grid-institutes:grid.410775.0 schema:alternateName Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan
364 schema:name Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan
365 rdf:type schema:Organization
366 grid-institutes:grid.410802.f schema:alternateName Saitama Medical University, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan
367 schema:name Saitama Medical University, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan
368 rdf:type schema:Organization
369 grid-institutes:grid.410814.8 schema:alternateName Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan
370 schema:name Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan
371 rdf:type schema:Organization
372 grid-institutes:grid.411205.3 schema:alternateName Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan
373 schema:name Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan
374 rdf:type schema:Organization
375 grid-institutes:grid.412568.c schema:alternateName Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan
376 schema:name Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan
377 rdf:type schema:Organization
378 grid-institutes:grid.430047.4 schema:alternateName Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan
379 schema:name Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, 38 Moroyama, 350-0495, Iruma-gun, Saitama, Japan
380 rdf:type schema:Organization
381 grid-institutes:grid.489169.b schema:alternateName Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan
382 schema:name Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan
383 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...